# Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB

> **NCT05295212** · PHASE2 · RECRUITING · sponsor: **Hunan Province Tumor Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT05295212
- **Lead sponsor:** Hunan Province Tumor Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-01
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-07-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05295212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05295212, "Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05295212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*